Nat Biotech:microRNA标靶技术为流感病毒研究保驾护航

2013-08-15 koo bio360

日前,来自美国西奈山伊坎医学院的研究人员提出了一种为禽流感病毒研究加设安全措施的方法。新方法能进一步加强病毒基因功能研究的安全性,并降低人类因接触实验室病毒而受感染的风险。相关研究论文在线刊登在了近期的《自然-生物技术》(Nature Biotechnology)杂志上。【原文下载】 直接接触禽鸟是目前人类感染禽流感病毒的主要途径,虽然禽流感病毒可能还未获得“人传人”的能力,但是也有研究显示

日前,来自美国西奈山伊坎医学院的研究人员提出了一种为禽流感病毒研究加设安全措施的方法。新方法能进一步加强病毒基因功能研究的安全性,并降低人类因接触实验室病毒而受感染的风险。相关研究论文在线刊登在了近期的《自然-生物技术》(Nature Biotechnology)杂志上。【原文下载

直接接触禽鸟是目前人类感染禽流感病毒的主要途径,虽然禽流感病毒可能还未获得“人传人”的能力,但是也有研究显示,基因变异后的禽流感病毒能通过空气飞沫,在雪貂之间有限传播(雪貂是研究人类流感最理想的动物模型)。病毒基因功能研究能有助于防止流感在全球蔓延,但用作实验的流感病毒有机会被释放,不论是无意或是有意。

虽然这些研究已经有具体的安全准则,但研究人员设计了一种策略,能进一步确保实验室内外的安全。不同物种会表达不同的 microRNA (能抑制特定基因的微小核糖核酸)。研究人员相信,带有 microRNA 标靶的流感病毒,会在感染带有那种 microRNA 的物种细胞后,停止表达和复制。他们发现了一种表达在人类和小鼠,而不在鼬肺部的 microRNA ,然后把该 microRNA 标靶插入流感病毒的基因序列。

研究发现,这样的流感病毒能在动物之间传播,但受感染的小鼠却没有发病。研究人员目前不能保证这种病毒对人类无害,但至少为用作实验室研究的病原体添加了多一层物理保障。

原始出处:

Ryan A Langlois, Randy A Albrecht, Brian Kimble, Troy Sutton, Jillian S Shapiro, Courtney Finch, Matthew Angel, Mark A Chua, Ana Silvia Gonzalez-Reiche, Kemin Xu, Daniel Perez, Adolfo García-Sastre& Benjamin R tenOever. microRNA -based strategy to mitigate the risk of gain-of-function influenza studies. Nature Biotechnology, 11 August 2013; doi:10.1038/nbt.2666 【原文下载

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1927597, encodeId=3b58192e597e3, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Mon Nov 18 05:47:00 CST 2013, time=2013-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857303, encodeId=1fa3185e30341, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Jul 20 00:47:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084085, encodeId=2acd2084085be, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu May 01 07:47:00 CST 2014, time=2014-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916973, encodeId=703219169e32d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Aug 20 00:47:00 CST 2013, time=2013-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652080, encodeId=eba71652080bc, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Tue Feb 25 00:47:00 CST 2014, time=2014-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879628, encodeId=844c18e9628b4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Aug 17 19:47:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435656, encodeId=63c0143565604, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 17 04:47:00 CST 2013, time=2013-08-17, status=1, ipAttribution=)]
    2013-11-18 cathymary
  2. [GetPortalCommentsPageByObjectIdResponse(id=1927597, encodeId=3b58192e597e3, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Mon Nov 18 05:47:00 CST 2013, time=2013-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857303, encodeId=1fa3185e30341, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Jul 20 00:47:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084085, encodeId=2acd2084085be, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu May 01 07:47:00 CST 2014, time=2014-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916973, encodeId=703219169e32d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Aug 20 00:47:00 CST 2013, time=2013-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652080, encodeId=eba71652080bc, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Tue Feb 25 00:47:00 CST 2014, time=2014-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879628, encodeId=844c18e9628b4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Aug 17 19:47:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435656, encodeId=63c0143565604, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 17 04:47:00 CST 2013, time=2013-08-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1927597, encodeId=3b58192e597e3, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Mon Nov 18 05:47:00 CST 2013, time=2013-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857303, encodeId=1fa3185e30341, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Jul 20 00:47:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084085, encodeId=2acd2084085be, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu May 01 07:47:00 CST 2014, time=2014-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916973, encodeId=703219169e32d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Aug 20 00:47:00 CST 2013, time=2013-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652080, encodeId=eba71652080bc, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Tue Feb 25 00:47:00 CST 2014, time=2014-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879628, encodeId=844c18e9628b4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Aug 17 19:47:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435656, encodeId=63c0143565604, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 17 04:47:00 CST 2013, time=2013-08-17, status=1, ipAttribution=)]
    2014-05-01 xjy02
  4. [GetPortalCommentsPageByObjectIdResponse(id=1927597, encodeId=3b58192e597e3, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Mon Nov 18 05:47:00 CST 2013, time=2013-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857303, encodeId=1fa3185e30341, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Jul 20 00:47:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084085, encodeId=2acd2084085be, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu May 01 07:47:00 CST 2014, time=2014-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916973, encodeId=703219169e32d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Aug 20 00:47:00 CST 2013, time=2013-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652080, encodeId=eba71652080bc, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Tue Feb 25 00:47:00 CST 2014, time=2014-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879628, encodeId=844c18e9628b4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Aug 17 19:47:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435656, encodeId=63c0143565604, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 17 04:47:00 CST 2013, time=2013-08-17, status=1, ipAttribution=)]
    2013-08-20 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=1927597, encodeId=3b58192e597e3, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Mon Nov 18 05:47:00 CST 2013, time=2013-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857303, encodeId=1fa3185e30341, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Jul 20 00:47:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084085, encodeId=2acd2084085be, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu May 01 07:47:00 CST 2014, time=2014-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916973, encodeId=703219169e32d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Aug 20 00:47:00 CST 2013, time=2013-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652080, encodeId=eba71652080bc, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Tue Feb 25 00:47:00 CST 2014, time=2014-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879628, encodeId=844c18e9628b4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Aug 17 19:47:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435656, encodeId=63c0143565604, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 17 04:47:00 CST 2013, time=2013-08-17, status=1, ipAttribution=)]
    2014-02-25 shock_melon
  6. [GetPortalCommentsPageByObjectIdResponse(id=1927597, encodeId=3b58192e597e3, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Mon Nov 18 05:47:00 CST 2013, time=2013-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857303, encodeId=1fa3185e30341, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Jul 20 00:47:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084085, encodeId=2acd2084085be, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu May 01 07:47:00 CST 2014, time=2014-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916973, encodeId=703219169e32d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Aug 20 00:47:00 CST 2013, time=2013-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652080, encodeId=eba71652080bc, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Tue Feb 25 00:47:00 CST 2014, time=2014-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879628, encodeId=844c18e9628b4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Aug 17 19:47:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435656, encodeId=63c0143565604, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 17 04:47:00 CST 2013, time=2013-08-17, status=1, ipAttribution=)]
    2013-08-17 liye789132251
  7. [GetPortalCommentsPageByObjectIdResponse(id=1927597, encodeId=3b58192e597e3, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Mon Nov 18 05:47:00 CST 2013, time=2013-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857303, encodeId=1fa3185e30341, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Sun Jul 20 00:47:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084085, encodeId=2acd2084085be, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu May 01 07:47:00 CST 2014, time=2014-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916973, encodeId=703219169e32d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Aug 20 00:47:00 CST 2013, time=2013-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652080, encodeId=eba71652080bc, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Tue Feb 25 00:47:00 CST 2014, time=2014-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879628, encodeId=844c18e9628b4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Aug 17 19:47:00 CST 2013, time=2013-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435656, encodeId=63c0143565604, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 17 04:47:00 CST 2013, time=2013-08-17, status=1, ipAttribution=)]
    2013-08-17 zhouqu_8

相关资讯

中科院启动人感染H7N9禽流感病毒攻关研究

记者8日从中国科学院获悉,根据当前人感染H7N9禽流感疫情,立足疫情防控国家需求,围绕疫情防控科学评判,该院已启动“人感染H7N9禽流感病毒科技攻关研究”。中科院组织所属微生物研究所、武汉病毒研究所、上海巴斯德研究所、生物物理研究所、北京基因组研究所、上海药物研究所、动物研究所、昆明动物研究所、中国科学技术大学等科研机构,并与临床单位和中国疾病预防控制中心协同合作,重点发挥基因组、生物信息学分析和

CSB:农科院专家率先揭示H7N9流感病毒来源

最新的一项研究提示,近期在我国导致人感染的新型H7N9流感病毒与同一时期存在于活禽市场上的H7N9禽流感病毒高度同源,为采取进一步防治措施提供了依据。 该项研究论文将于近期发表于《科学通报》英文版,从病原学角度初步揭示了新型H7N9流感病毒的特征,由中国农业科学院哈尔滨兽医研究所陈化兰研究员和李呈军研究员担任通讯作者撰写。 2013年3月31日,国家卫生和计划生育委员会公布了上海和安徽出现的新

JID:流感患者或可通过气溶胶传播流感病毒

流感被认为主要是通过飞沫传播(微粒直径>5μm,并且在3-6英尺内沉淀);然而在某些特殊情况下,空气传播(微粒直径<5μm ,在空气中处于悬浮状态)也被认为与流感传播有关,比如流感病毒通过气溶胶进行传播。在美国职业安全与卫生管理局(OSHA)和公共卫生流行病学专家间,关于空气传播在流感发生过程所起作用的讨论早已展开,特别是在2009-2010年流感季节期间H1N1病毒株大规模爆发之时。 B

JBC:三种抗肿瘤药物或具有抗流感疗效

       赫尔辛基大学芬兰分子医学研究所的医疗系统病毒学小组(FIMM) 与国内和国外合作者们共同研究,开发出一种可以识别潜在抗流感药物的细胞监控手段。研究人员发现了两种具有抗流感活性的抗肿瘤药物:obatoclax 以及gemcitabine,并且证实了已知药物saliphenylhalamide的抗流感疗效。   该研究已被Journal of Biolo

北京进入流感高峰期 甲型H1N1病毒正成为主导毒株

  北京市疾病预防控制中心1月5日称,北京已进入流感活动高峰期,未来一段时期内将维持在较高的活动水平。现阶段北京市为甲型H1N1流感病毒和甲型H3N2亚型流感病毒共同流行,且甲型H1N1流感病毒逐渐转变为主导毒株。   北京市流感监测数据显示,2012年第52周(12月24日-12月30日)北京市二级以上医疗机构累计监测门急诊就诊人数约104万人,流感样病例占2.75%,流感样病例人数28567

H7N9流感病毒的感染途径仍然未知

H7N9流感病毒感染人类的途径依旧是一个谜,特别是有一位顶级流感专家表示很多感染者都没有家禽接触史。 虽然周四来自中国的报道称,官方正在调查可能导致家庭聚集性发病的原因,但中国CDC和WHO官方依然表示目前没有人传人的证据。 中国疾控中心卫生应急中心主任冯子健说,调查人员正在努力弄清两个儿子与他们87岁高龄的父亲间是否存在传染。这位父亲于3月4日死亡——这是报道的首例与新型禽流感病毒感染有关的